The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort

Journal of Infection

Volumn 66, Issue 1, 2013, Pages 75-79

  Patel, Sheel ^a   Shin, Gee Yen ^a   Wijewardana, Ishan ^b   Vitharana, Sasiri Rivinda ^c   Cormack, Ian ^c   Pakianathan, Mark ^a   Harrison, Thomas S ^a,b   Bicanic, Tihana ^a,b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Cryptococcal antigen; Cryptococcal meningitis; Cryptococcosis; HIV; Prevalence; United Kingdom

Indexed keywords

AMPHOTERICIN B; CRYPTOCOCCAL ANTIGEN; FLUCONAZOLE; FLUCYTOSINE; FUNGUS ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASYMPTOMATIC INFECTION; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; NEGRO; PREVALENCE; RETROSPECTIVE STUDY; UNITED KINGDOM; URBAN POPULATION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIGENS, FUNGAL; FEMALE; HUMANS; LONDON; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84870734557     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.09.014     Document Type: Article

References (23)

1. Park B.J., Wannemuehler K.A., Marston B.J., Govender N., Pappas P.G., Chiller T.M. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 23:525-530.
2. Jarvis J.N., Bicanic T., Harrison T.S. Management of cryptocococcal meningoencephalitis in both developed and developing countries. Cryptococcus neoformans: from human pathogen to model yeast 2011, ASM Press, [chapter 42]. J. Heitman (Ed.).
3. Van der Horst C.M., Saag M.S., Cloud G.A., Hammill R.J., Graybill R., Sobel J.D., et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997, 337:15-21.
4. Bicanic T., Muzoora C., Brouwer A., Meintjes G., Longley N., Taseera K., et al. Rate of clearance of infection is independently associated with clinical outcome in HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 2009, 49:702-709.
5. Castelnuovo B., Manabe Y.C., Kiragga A., Kamya M., Easterbrook P., Kambugu A. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis 2009, 49:965-972.
6. Velagapudi R., Hsueh Y.P., Geunes-Boyer S., Wright J.R., Heitman J. Spores as infectious propagules of Cryptococcus neoformans. Infect Immun 2009, 77:4345-4355.
7. Garcia-Hermoso D., Janbon G., Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol 1999, 37:3204-3209.
8. French N., Gray K., Watera C., Nakiyingi J., Lugada E., Moore M., et al. Cryptococcal infection in a cohort of HIV-1 - infected Ugandan adults. AIDS 2002, 16:1031-1038.
9. Jarvis J.N., Lawn S.D., Vogt M., Bangani N., Wood R., Harrison T.S. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009, 48:856-862.
10. Liechty C.A., Solberg P., Were W., Ekwaru J.P., Ransom R.L., Weidle P.J., et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 2007, 12:929-935.
11. Meya D.B., Manabe Y.C., Castelnuovo B., Cook B.A., Ebireer A.M., Kambugu A., et al. Serum cryptococcal antigen (CRAG) screening is a cost-effective method to prevent death in HIV-infected persons with CD4 ≤100/uL starting HIV therapy in resource-limited settings. Clin Infect Dis 2010, 51:448-455.
12. Mamoojee Y., Shakoor S., Gorton R.L., Sarfo S., Appiah L.T., Norman B., et al. Short Communication: low seroprevalence of cryptococcal antigenaemia in patien ts with advanced HIV infection enrolling in an antiretroviral programme in Ghana. Trop Med Int Health 2011, 16:53-56.
13. Desmet P., Kayembe K.D., De Vroey C. The value of cryptococcal serum antigen screening among HIV-positive/AIDS patients in Kinshasa, Zaire. AIDS 1989, 3:77-78.
14. Jarvis JN, Harrison T, Lawn S, Meintjes G, Wood R, Cleary S. Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. IAS Rome, 2011, WELBD02-Oral Abstract.
15. Govender N. 18th Congress of the International Society for Human and Animal Mycology, Berlin, 11-15 June 2012, abstract C3.
16. Nelson M., Manji H., Wilkins E. Central nervous system opportunistic infections. British HIV Association and British Infection Association Guidelines for the Treatment of Opportunistic Infection in HIV-seropositive Individuals 2011. HIV Med 2011, 12(Suppl. 2):8-24.
17. Health Protection Agency HIV in the United Kingdom: 2011 Report 2011, Available at:, National Institute of Clinical Excellence, Increasing the uptake of HIV testing to reduce undiagnosed infection and prevent transmission among black African communities living in England. Available at:. http://guidance.nice.org.uk/PH33.
18. Chen M., Rhodes P.H., Hall I.H., Kilmarx P.H., Branson B.M., Valleroy L.A. Centers for disease control and prevention (CDC). Prevalence of undiagnosed HIV infection among persons aged ≥13 years-National HIV Surveillance System, United States, 2005-2008. MMWR Morb Mortal Wkly Rep 2012 Jun 15, 61(Suppl):57-64.
19. National Institute of Clinical Excellence Increasing the uptake of HIV testing to reduce undiagnosed infection and prevent transmission among black African communities living in England http://guidance.nice.org.uk/PH33.
20. Asboe D., Aitken C., Boffito M., Booth C., Cane P., Fakoya A., et al. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med 2012, 13:1-44.
21. Jarvis J.N., Percival A., Bauman S., Pelfrey J., Meintjes G., Williams G.N., et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 2011, 53:1019-1023.
22. Alpha Laboratories. Crytpcococcal Antigen Systems. Available at: [accessed 22.06.12]. http://www.alphalabs.co.uk/product-information/diagnostic-products/mycology/cryptococcal-antigen-systems.aspx.
23. Jarvis JN, Govender N, Chiller T, Park BJ, Longley N, Meintjes G, et al. Cryptococcal antigen screening and pre-emptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation. J Int Assoc Physicians AIDS Care (Chic) 2012 Sep 26. [Epub ahead of print].